SCHEMBL4421899

SCHEMBL4421899

COc1cc(-c2noc(COC3CCN(C(=O)OC(C)(C)C)CC3)n2)ccc1SC

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.68
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
PDE4A P27815 2/20 0.45
PDE4B Q07343 2/20 0.45
PDE4C Q08493 2/20 0.45
PDE4D Q08499 2/20 0.45
HDAC4 P56524 3/20 0.43
PIK3CD O00329 2/20 0.43
PIK3CA P42336 2/20 0.43
PIK3CB P42338 2/20 0.43
PIK3CG P48736 2/20 0.43
HPGD P15428 2/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419008 0.91 GPR119 (0.73) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL4415889 0.90 GPR119 (0.70) GPR119ALDH1A1SMN1; SMN2HDAC4HDAC6
SCHEMBL4417299 0.89 GPR119 (0.69) GPR119SMN1; SMN2HDAC4MAPTHDAC6
SCHEMBL4416595 0.89 GPR119 (0.69) GPR119SMN1; SMN2HDAC4MAPTHDAC6
SCHEMBL4413067 0.88 GPR119 (0.67) GPR119ALDH1A1SMN1; SMN2PDE4APDE4B
SCHEMBL4419628 0.86 GPR119 (0.65) GPR119ALDH1A1SMN1; SMN2PDE4APDE4B
SCHEMBL4416063 0.86 GPR119 (0.78) GPR119ALDH1A1SMN1; SMN2HDAC4HPGD
SCHEMBL14640607 0.84 GPR119 (0.74) GPR119ALDH1A1PDE4APDE4BPDE4C
SCHEMBL17122217 0.82 GPR119 (0.84) GPR119HDAC4HDAC6
SCHEMBL4415733 0.82 GPR119 (0.69) GPR119SMN1; SMN2HDAC4MAPTHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885ALDH1A1 1059/4885SMN1; SMN2 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.